The Relationship Of Serum Testosterone To Erectile Function In Normal Aging Men

Andrology Division, Department of Urology, Santa Casa Hospital and Fundação Faculdade Federal de Ciências Médicas, Porto Alegre, Brazil.
The Journal of Urology (Impact Factor: 4.47). 05/2002; 167(4):1745-8. DOI: 10.1097/00005392-200204000-00037
Source: PubMed


We evaluated the variation in serum testosterone in normal aging men and its relationship with erectile function.
In a study that was not community based and during a free screening program for prostate cancer 1,071 men were invited to complete a sexual activity questionnaire, that is the abridged 5-item version of the International Index of Erectile Function (IIEF-5), as a diagnostic tool for erectile dysfunction. Possible scores on the IIEF-5 are 1 to 25 and erectile dysfunction was classified into 5 categories based on the scores, namely severe-1 to 7, moderate-8 to 11, mild to moderate-12 to 16, mild-17 to 21 and none-22 to 25. Serum total testosterone was measured between 8:00 and 10:00 a.m. in all men.
Of the 1,071 men 965 (90.1%) were included in this study, of whom 88% were white and 12% were black. Mean age was 60.7 years. In this sample the prevalence of all degrees of erectile dysfunction was estimated to be 53.9%. The degree of erectile dysfunction was mild in 21.5% of cases, mild to moderate in 14.1%, moderate in 6.3% and severe in 11.9%. According to age the erectile dysfunction rate was 36.4% in the 40 to 49, 42.5% in the 50 to 59, 58.1% in the 60 to 69, 79.4% in the 70 to 79 and 100% in the 80 years and older groups (p <0.05). The variation in mean serum total testosterone in the age groups was not statistically significantly different (p >0.05). Pearson coefficients of age and total testosterone did not reveal any significant correlation (r = 0.00376, p = 0.907), similar to IIEF-5 score and total testosterone (r = 0.0163, p = 0.612). However, analysis of the variables IIEF-5 and age showed a statistically significant inverse or negative relationship (r = -0.3449, p <0.05).
Erectile dysfunction showed a clear association with aging but no consistent correlation of total testosterone with erectile condition was identified.

Download full-text


Available from: Claudio Teloken
  • Source
    • "There is general agreement that total testosterone levels above 12 nmol/L (346 ng/dL) or free testosterone levels above 250 pmol/L (72 pg/mL) do not require testosterone substitution. Similarly, testosterone supplementation should be started according to the reference levels given in the recommendations of the ISA-ISSAM-EAU [10] when serum total testosterone levels are below 8 nmol/L (231 ng/dL) or free testosterone levels are below 180 pmol/L (52 pg/mL) and when serum total testosterone levels are between 12 and 8 nmol/L or free testosterone levels are between 250 and 180 pmol/L in patients with symptoms of testosterone deficiency. So we considered Normal Testosterone (NT) patients who had total testosterone levels above 12 nmol/L (346 ng/dL) and free testosterone levels above 250 pmol/L (72 pg/mL), and Low Testosterone (LT) patients who had testosterone levels below 12 nmol/L (346 ng/dL) and free testosterone levels below 250 pmol/L (72 pg/mL). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Reduced libido is widely considered the most prominent symptomatic reflection of low testosterone (T) levels in men. Testosterone deficiency (TD) afflicts approximately 30% of men aged 40-79 years. This study seeks to evaluate the effect of a new natural compound "tradamixina "in order to improve male sexual function in elderly men, particularly libido and possible erectile dysfunction, versus administration of tadalafil 5 mg daily. Seventy patients (67.3± 3.7 years) with stable marital relations and affected by reduced libido, with or without erectile dysfunction were recruited. They were randomly separated in 2 groups A-B of 35. Group A was administered twice a day a new compound "Tradamixina" (150 mg of Alga Ecklonia Bicyclis, 396 mg of Tribulus Terrestris and 144 mg of D-Glucosamine and N-Acetyl-D-Glucosamine) for two months, while Group B was administered tadalafil 5 mg daily, for two months. At visit and after 60 days of treatment patients were evaluated by means of detailed medical and sexual history, clinical examination, laboratory investigations (Total and Free T), instrumental examination (NPTR- nocturnal penile tumescence and rigidity test- with Rigiscan). Patients completed a self-administered IIEF questionnaire (The international index of erectile function) and SQoLM questionnaire (Sexual quality of life Questionnarie-Male). The results pre and post treatment were compared by Student t test (p<0.005). After 2 months of treatment in group A serum TT levels (230±18 ng/dl vs 671±14 ng/dl ) and FT levels(56± 2.4 pg/ml vs 120± 3.9pg/ml) increased, while in group B serum TT levels (245±12 ng/dl vs 247±15 ng/dl ) and FT levels(53± 0.3 pg/ml vs 55± 0.5pg/ml) increased not statistically significant. The patient's numbers with negative NPTR improved after treatment in group A and B (15 vs 18 and 13 vs 25 respectively). The IIEF total score in group A increased after treatment with tradamixina (15±1.5 vs 29.77±1.2); the IIEF total score in group B increased slightly (12±1.3 vs 23.40±1.2). The SQoLM total score improved in both groups (A:16±2,3 vs 33±4,1 and B: 16±3,4 vs 31±2,1). The treatment twice a day with "Tradamixina" for 2 months improved libido in elderly men without side effects of Tadalafil.
    Full-text · Article · Nov 2012 · BMC Surgery
  • Source
    • "However, testosterone has also been shown to increase the expression of PDE5 [62]. Thus, testosterone induces an overall modest effect on erection alone, as observed in studies that found no significant association between ED and hypogonadism in normal healthy populations [63]. This dual function has been suggested to allow testosterone to effectively regulate the timing of erection pertaining to sexual desire [58,64]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Testosterone is the principal androgen in the human male. The decline of testosterone with aging was recognized to be associated with a number of symptoms and signs that reduce the quality of life and that may even have severe, debilitating consequences. Clinically, late-onset hypogonadism (LOH) is diagnosed by use of biochemical and clinical measures. Despite published guidelines and recommendations, however, uncertainty surrounds the profile of clinical symptoms as well as the biochemical threshold of diagnosis. Clinicians should be aware of these shortcomings while adhering to the guidelines. Current treatment methods are centered on restoring testosterone to mid to lower levels of young men with natural testosterone replacements. Although recent studies have highlighted possible additional benefits involving improvement of systemic disorders, the goal of treatment is to improve sexual function, while observing for adverse effects in the prostate. Overall, the problem of LOH in debilitating the quality of life and well-being is real, and by following proper guidelines with attentiveness to the results of treatment trials, testosterone replacement therapy presents a safe and effective treatment option.
    Full-text · Article · Nov 2011 · Korean journal of urology
  • Source
    • "The treatment of testicular cancer can result in insufficient Leydig cell function (Nord et al, 2003) or even in reduced serum testosterone levels (Gerl et al, 2001), regardless of treatment modalities. The correlation between low testosterone levels and erectile dysfunction is still controversial (Rhoden et al, 2002a; Shabsigh, 2003). Furthermore, cisplatin-based chemotherapy can dose dependently damage the peripheral nerves and the small vascular system. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Testis cancer is a disease that directly affects a man's sense of masculinity and involves treatments compromising sexual function. The aim of this study was to investigate the prevalence of sexual dysfunction and the influence of chronic pain on sexuality in long-term testis cancer survivors. Thus, we examined 539 patients after they had one testis removed because of a testicular germ cell tumor. Having completed oncologic therapy, all patients received a detailed questionnaire asking about the occurrence and clinical presentation of testis pain before and after orchiectomy. In addition, items from the abridged International Index of Erectile Function and Brief Sexual Function Inventory were used to gain precise information on individual sexual function. Overall, 34.5% of our testicular cancer survivors complained of reduced sexual desire, and sexual activity was reduced in 41.6%. Erectile dysfunction was present in up to 31.5% of patients. In 24.4%, the ability to maintain an erection during intercourse was impaired. Ejaculatory disorders (premature, delayed, retrograde, or anejaculation) occurred in 84.9% of our testis cancer survivors. A total of 32.4% of our participants experienced a reduced intensity of orgasm, and 95.4% experienced reduced overall sexual satisfaction. There was a significant correlation between the occurrence of chronic pain symptoms and the relative frequency and intensity of erectile dysfunction, inability to maintain an erection, ejaculation disorders, and reduced intensity of orgasm. In conclusion, chronic pain has a negative impact on sexuality in testis cancer survivors.
    Preview · Article · Apr 2011 · Journal of Andrology
Show more